<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215540</url>
  </required_header>
  <id_info>
    <org_study_id>KL4-BPD-01</org_study_id>
    <nct_id>NCT00215540</nct_id>
  </id_info>
  <brief_title>SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windtree Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Windtree Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to
      prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia
      (BPD), in premature infants who have required continued intubation and received surfactants
      for the prevention or treatment of respiratory distress syndrome (RDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the safety and tolerability of SURFAXIN administration in the first weeks of life
      as a therapeutic approach for prevention of BPD. Determine whether treatment with SURFAXIN
      during the first two to three weeks of life can decrease the proportion of infants on
      mechanical ventilation or oxygen or the incidence of death or BPD in VLBW infants when
      assessed at 28 days of life and 36 weeks post-menstrual age (as determined by the need for
      supplemental oxygen).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Concerns related to availability of drug product
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Death or Bronchopulmonary Dysplasia (BPD) at 36 Weeks</measure>
    <time_frame>36 weeks post-menstrual age (PMA)</time_frame>
    <description>Number of participants who died or developed BPD, defined as oxygen requirement at 36 Weeks post-menstrual age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>36 weeks PMA</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BPD at 28 Days</measure>
    <time_frame>28 days of life</time_frame>
    <description>BPD at 28 days of life, as determined by the need for supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPD at 36 Weeks</measure>
    <time_frame>36 weeks PMA</time_frame>
    <description>BPD at 36 weeks PMA as determined by the need for supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Receiving Mechanical Ventilation (MV)</measure>
    <time_frame>36 weeks PMA</time_frame>
    <description>Number of days receiving mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>36 weeks PMA</time_frame>
    <description>Number of days receiving supplemental oxygen through 36 weeks PMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Fraction of Inspired Oxygen (FiO₂)</measure>
    <time_frame>15 minutes prior to dose 1, 2 hours post dose 1, 6 hours post dose 1, 24 hours post dose 1, and daily from Study Day 2 to Study Day 25 and Day of Life 28</time_frame>
    <description>AUC for FiO₂calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for Mean Arterial Pressure (MAP)</measure>
    <time_frame>15 minutes prior to dose 1, 2 hours post dose 1, 6 hours post dose 1, 24 hours post dose 1, and daily from Study Day 2 to Study Day 25, and day of life 28</time_frame>
    <description>AUC for MAP (in mm Hg) calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death or BPD at 28 Days</measure>
    <time_frame>28 days of life</time_frame>
    <description>Death or BPD, defined as oxygen requirement at 28 days of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in Hospital</measure>
    <time_frame>36 weeks PMA</time_frame>
    <description>The number of days spent in the hospital through 36 weeks PMA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Premature Birth</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>SURFAXIN High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SURFAXIN Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham air using 3.0 mL/kg volume of air</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucinactant 175 mg/kg</intervention_name>
    <description>Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).</description>
    <arm_group_label>SURFAXIN High Dose</arm_group_label>
    <other_name>SURFAXIN</other_name>
    <other_name>Lucinactant</other_name>
    <other_name>Surfactant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucinactant 90 mg/kg</intervention_name>
    <description>Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).</description>
    <arm_group_label>SURFAXIN Low Dose</arm_group_label>
    <other_name>SURFAXIN</other_name>
    <other_name>Lucinactant</other_name>
    <other_name>Surfactant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sham Air</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infants between 600 and 900 grams birth weight

          -  Intubated and on mechanical ventilation

          -  Sustained (&gt;= 30 minutes) fraction of inspired oxygen (FiO₂) &gt;= 0.30 within 8 hours
             prior to randomization

        Exclusion Criteria:

          -  Mother has prolonged rupture of membranes ≥ 2 weeks

          -  Culture-proven sepsis

          -  High grade intraventricular hemorrhage (IVH)

          -  Congenital heart disease

          -  Congential anomalies inconsistent with life or likely to confound efficacy or safety
             endpoints

          -  FiO₂≥ 0.80 and mean airway pressure (MAP) ≥ 12 cmH2O at day of life (DOL) 3

          -  FiO₂&lt; 0.25 at any time between meeting the entry criteria to immediately prior to
             randomization

          -  Concomitant use of any other surfactant within the first 48 hours of life

          -  Prior use of nitric oxide

          -  Prior use of steroids

          -  Current participation in any other clinical trial or has received an experimental drug
             or used an experimental device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Guardia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Windtree Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew M Laughon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Discovery Laboratories, Inc.</name>
      <address>
        <city>Warrington</city>
        <state>Pennsylvania</state>
        <zip>18976-3646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Laughon M, Bose C, Moya F, Aschner J, Donn SM, Morabito C, Cummings JJ, Segal R, Guardia C, Liu G; Surfaxin Study Group. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics. 2009 Jan;123(1):89-96. doi: 10.1542/peds.2007-2680. Erratum in: Pediatrics. 2009 May;123(5):1436.</citation>
    <PMID>19117865</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>April 2, 2012</results_first_submitted>
  <results_first_submitted_qc>May 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2012</results_first_posted>
  <last_update_submitted>May 11, 2012</last_update_submitted>
  <last_update_submitted_qc>May 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-blind</keyword>
  <keyword>Low Birth Weight</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Premature Birth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SURFAXIN High Dose</title>
          <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>SURFAXIN Low Dose</title>
          <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Sham air using 3.0 mL/kg volume of air</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew from study medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SURFAXIN High Dose</title>
          <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>SURFAXIN Low Dose</title>
          <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Sham air using 3.0 mL/kg volume of air</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="1.68"/>
                    <measurement group_id="B2" value="25.5" spread="1.43"/>
                    <measurement group_id="B3" value="25.7" spread="1.36"/>
                    <measurement group_id="B4" value="25.8" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Death or Bronchopulmonary Dysplasia (BPD) at 36 Weeks</title>
        <description>Number of participants who died or developed BPD, defined as oxygen requirement at 36 Weeks post-menstrual age</description>
        <time_frame>36 weeks post-menstrual age (PMA)</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Death or Bronchopulmonary Dysplasia (BPD) at 36 Weeks</title>
          <description>Number of participants who died or developed BPD, defined as oxygen requirement at 36 Weeks post-menstrual age</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All-cause Mortality</title>
        <time_frame>36 weeks PMA</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: No difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BPD at 28 Days</title>
        <description>BPD at 28 days of life, as determined by the need for supplemental oxygen</description>
        <time_frame>28 days of life</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>BPD at 28 Days</title>
          <description>BPD at 28 days of life, as determined by the need for supplemental oxygen</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.944</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BPD at 36 Weeks</title>
        <description>BPD at 36 weeks PMA as determined by the need for supplemental oxygen</description>
        <time_frame>36 weeks PMA</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>BPD at 36 Weeks</title>
          <description>BPD at 36 weeks PMA as determined by the need for supplemental oxygen</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Receiving Mechanical Ventilation (MV)</title>
        <description>Number of days receiving mechanical ventilation</description>
        <time_frame>36 weeks PMA</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Days Receiving Mechanical Ventilation (MV)</title>
          <description>Number of days receiving mechanical ventilation</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="23.3"/>
                    <measurement group_id="O2" value="42.1" spread="26.4"/>
                    <measurement group_id="O3" value="35.8" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Supplemental Oxygen</title>
        <description>Number of days receiving supplemental oxygen through 36 weeks PMA</description>
        <time_frame>36 weeks PMA</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Supplemental Oxygen</title>
          <description>Number of days receiving supplemental oxygen through 36 weeks PMA</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="16.8"/>
                    <measurement group_id="O2" value="63.0" spread="19.3"/>
                    <measurement group_id="O3" value="55.7" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for Fraction of Inspired Oxygen (FiO₂)</title>
        <description>AUC for FiO₂calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
        <time_frame>15 minutes prior to dose 1, 2 hours post dose 1, 6 hours post dose 1, 24 hours post dose 1, and daily from Study Day 2 to Study Day 25 and Day of Life 28</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Fraction of Inspired Oxygen (FiO₂)</title>
          <description>AUC for FiO₂calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>Percent O₂*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.14"/>
                    <measurement group_id="O2" value="0.41" spread="0.16"/>
                    <measurement group_id="O3" value="0.38" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.843</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.543</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.537</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve for Mean Arterial Pressure (MAP)</title>
        <description>AUC for MAP (in mm Hg) calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
        <time_frame>15 minutes prior to dose 1, 2 hours post dose 1, 6 hours post dose 1, 24 hours post dose 1, and daily from Study Day 2 to Study Day 25, and day of life 28</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Mean Arterial Pressure (MAP)</title>
          <description>AUC for MAP (in mm Hg) calculated using the trapezoidal rule. Missing data imputed using last observation carried forward</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>arterial pressure (mm Hg)*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="3.38"/>
                    <measurement group_id="O2" value="6.93" spread="4.13"/>
                    <measurement group_id="O3" value="6.34" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.813</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.275</p_value>
            <method>ANOVA</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Death or BPD at 28 Days</title>
        <description>Death or BPD, defined as oxygen requirement at 28 days of life</description>
        <time_frame>28 days of life</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Death or BPD at 28 Days</title>
          <description>Death or BPD, defined as oxygen requirement at 28 days of life</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days in Hospital</title>
        <description>The number of days spent in the hospital through 36 weeks PMA</description>
        <time_frame>36 weeks PMA</time_frame>
        <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
        <group_list>
          <group group_id="O1">
            <title>SURFAXIN High Dose</title>
            <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SURFAXIN Low Dose</title>
            <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Sham air using 3.0 mL/kg volume of air</description>
          </group>
        </group_list>
        <measure>
          <title>Days in Hospital</title>
          <description>The number of days spent in the hospital through 36 weeks PMA</description>
          <population>A sample size of 70 per arm is sufficient to demonstrate a 20% relative risk reduction. All randomized infants were analyzed (intent-to-treat)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="11.72"/>
                    <measurement group_id="O2" value="70.0" spread="10.06"/>
                    <measurement group_id="O3" value="68.6" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.516</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>ANOVA</method>
            <method_desc>On rank adjusting for pooled study center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 36 weeks PMA</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SURFAXIN High Dose</title>
          <description>SURFAXIN (lucinactant) at 175 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>SURFAXIN Low Dose</title>
          <description>SURFAXIN (lucinactant) at 90 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Sham air using 3.0 mL/kg volume of air</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cardiac arrest neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retrolental fibro-dysplasia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Inguinal hernia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intestinal perforation NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Meconium ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sepsis NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Septicaemia serratia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Septicaemia staphylococcal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrasion NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hydrocephalus NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Renal failure neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary dysplasia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal apnoeic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumothorax NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary interstitial emphysema syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus repair</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory failure neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intracranial haemorrhage NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="20" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" events="41" subjects_affected="24" subjects_at_risk="45"/>
                <counts group_id="E2" events="37" subjects_affected="25" subjects_at_risk="47"/>
                <counts group_id="E3" events="38" subjects_affected="25" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia neonatal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia NOS</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="45"/>
                <counts group_id="E2" events="51" subjects_affected="20" subjects_at_risk="47"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retrolental fibro-dysplasia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="45"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="47"/>
                <counts group_id="E3" events="35" subjects_affected="29" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-oesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Inguinal hernia NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sepsis NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sepsis Neonatal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Septicaemia staphylococcal</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Tracheitis NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrasion NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood in stool</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" events="40" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E3" events="22" subjects_affected="16" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia NOS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary dysplasia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="45"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="47"/>
                <counts group_id="E3" events="38" subjects_affected="37" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal apnoeic attack</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="47"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal hypoxia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="18" subjects_at_risk="45"/>
                <counts group_id="E2" events="75" subjects_affected="25" subjects_at_risk="47"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory acidosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumothorax NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pulmonary interstitial emphysema syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Respiratory failure (exc neonatal)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus repair</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="47"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neonatal hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Segal</name_or_title>
      <organization>Discovery Laboratories, Inc.</organization>
      <phone>215-488-9300</phone>
      <email>rsegal@discoverylabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

